Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 19/20 | 0.72 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.72 |
| ▸ | NQO2 | P16083 | 1/20 | 0.72 |
| ▸ | SMC2 | O95347 | 1/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.60 |
| ▸ | SMC1A | Q14683 | 1/20 | 0.60 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.60 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.60 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4321805 | 0.88 | MAP2K1 (0.56) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL4326016 | 0.84 | MAP2K1 (0.55) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| Binimetinib SCHEMBL29363187 | 0.83 | MAP2K1 (1.00) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| Binimetinib SCHEMBL570088 | 0.83 | MAP2K1 (1.00) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL4334335 | 0.83 | MAP2K1 (0.53) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL13750471 | 0.83 | MAP2K1 (0.60) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL388476 | 0.79 | MAP2K1 (0.69) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL4418419 | 0.79 | MAP2K1 (0.76) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL25189605 | 0.77 | MAP2K1 (0.88) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL29990127 | 0.77 | MAP2K1 (0.88) | MAP2K1MAP2K2ABCB11NQO2SMC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576072-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576072-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576072-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20050153942-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153942-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | MAP2K1 77/4885MAP2K2 63/4885ABCB11 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.